Key Statistics
Market Cap$50.18M
P/E RatioN/A
Div. Yield—
EPS (TTM)-$2.93
52W High$76.00
52W Low$6.34
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
Employees23
Price Performance
1 Week-2.99%
3 Month-11.36%
1 Year+22.17%
FinancialsAnnual · QuiverQuant
Revenue$463,256
Assets$4.55M
Liabilities$22.61M
Net Income$22.46M loss
About
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York.
WebullFree stocks
Advanced charting, extended hours trading, and free stock for new accounts.
Analyze INKT with professional charts— Free to start
Price data sourced from Polygon.io (previous trading day close). Fundamentals from Alpha Vantage. Insider trades from SEC EDGAR. Cached via Cloudflare KV.